A quiet hope has started to grow among people living with stubborn cholesterol problems as researchers report early success ...

CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company pioneering a novel gene editing platform to overcome drug resistance in solid tumors, today announced the publication of a ...

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced mu ...

Immunometabolism have advanced the understanding of dynamic interplay between metabolic pathways and immune responses.

Sharpen your Mains answer-writing skills with GS-3 questions by following the thought process. Do not miss points to ponder ...

Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

A new gene therapy shows promise in controlling cholesterol by lowering bad LDL levels, potentially reducing the risk of ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 ...

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on ...